2023
Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023
Dalton A, Diallo A, Chard A, Moulia D, Deputy N, Fothergill A, Kracalik I, Wegner C, Markus T, Pathela P, Still W, Hawkins S, Mangla A, Ravi N, Licherdell E, Britton A, Lynfield R, Sutton M, Hansen A, Betancourt G, Rowlands J, Chai S, Fisher R, Danza P, Farley M, Zipprich J, Prahl G, Wendel K, Niccolai L, Castilho J, Payne D, Cohn A, Feldstein L, Group C, Group C, Saadeh K, Snyder R, Anderson M, Anguiano V, Nadle J, Rothrock G, Jones S, Duval L, Herlihy R, Stringer G, Weber R, Phan Q, Sosa L, Meek J, Lee M, Morrow A, Willut C, Carlson J, Kamis K, Nishiyama M, Simien G, Colasanti J, van der Woude T, Archer R, Finn L, Lam J, Moulton B, Peterson E, Bolan R, Garcia-Lopez G, Como-Sabetti K, Ruff A, Schneider D, Robinson T, Anderson B, Engesser K, McGuire S, Rowe A, Pride C, Mitchell J, Tourkina Y, Cieslak P, Fill M, Wiedeman C, Dumyati G, Felsen C, Lewnard J, Akoko B, Mansilla-Dubon K, Ndi D, Talbot H, Tiwari S, Wyatt D. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 553-558. PMID: 37200229, PMCID: PMC10205167, DOI: 10.15585/mmwr.mm7220a3.Peer-Reviewed Original ResearchConceptsAdjusted vaccine effectivenessVaccine effectivenessCase-control studyFull vaccinationEmerging Infections Program sitesEmergency use authorizationDuration of protectionPrevention of smallpoxImmunocompetent participantsImmunocompromised participantsControl patientsImmunization PracticesPartial vaccinationIntradermal injectionSubcutaneous injectionVaccinationMonkeypox casesAdministration routeDrug AdministrationVaccine accessLaboratory capacityTransgender adultsVaccineTransgender personsAdvisory CommitteeBacterial and viral infections among adults hospitalized with COVID‐19, COVID‐NET, 14 states, March 2020–April 2022
Shah M, Patel K, Milucky J, Taylor C, Reingold A, Armistead I, Meek J, Anderson E, Weigel A, Reeg L, Como‐Sabetti K, Ropp S, Muse A, Bushey S, Shiltz E, Sutton M, Talbot H, Chatelain R, Havers F, Team T. Bacterial and viral infections among adults hospitalized with COVID‐19, COVID‐NET, 14 states, March 2020–April 2022. Influenza And Other Respiratory Viruses 2023, 17: e13107. PMID: 36875205, PMCID: PMC9981874, DOI: 10.1111/irv.13107.Peer-Reviewed Original ResearchConceptsDay of admissionSARS-CoV-2 infectionHospitalized adultsViral infectionBacterial coinfectionCOVID-19Laboratory-confirmed SARS-CoV-2 infectionBacterial infectionsPopulation-based surveillance systemRhinovirus/enterovirusRespiratory syncytial virusBacterial pathogensCoV-2 virusClinical featuresClinical outcomesViral coinfectionSyncytial virusHuman metapneumovirusParainfluenza virusRisk factorsSterile sitesEndemic coronavirusesRelative riskRelevant bacterial pathogensGram-negative rods
2022
Drug use and severe outcomes among adults hospitalized with influenza, 2016–2019
Parisi C, Yousey‐Hindes K, Holstein R, O'Halloran A, Kirley P, Alden N, Anderson E, Kim S, McMahon M, Khanlian S, Spina N, Gaitan M, Shiltz E, Thomas A, Schaffner W, Talbot K, Crossland M, Cook R, Garg S, Meek J, Hadler J. Drug use and severe outcomes among adults hospitalized with influenza, 2016–2019. Influenza And Other Respiratory Viruses 2022, 17: e13052. PMID: 36300969, PMCID: PMC9835414, DOI: 10.1111/irv.13052.Peer-Reviewed Original ResearchConceptsSevere outcomesDrug useICU admissionMechanical ventilationInfluenza Hospitalization Surveillance NetworkInfluenza-associated outcomesSevere influenza outcomesPersistent public health problemChronic liver diseaseChronic lung diseasePublic health problemNon-Hispanic blacksLogistic regression modelsHispanics/LatinosSmoke tobaccoInfluenza vaccinationOpioid useImmunosuppressive conditionsInfluenza seasonSevere morbidityInfluenza infectionInfluenza outcomesLiver diseaseLung diseaseChronic conditions
2021
Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States
Hook SA, Hansen AP, Niesobecki SA, Meek JI, Bjork JKH, Kough EM, Peterson MS, Schiffman EK, Rutz HJ, Rowe AJ, White JL, Peel JL, Biggerstaff BJ, Hinckley AF. Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States. Vaccine 2021, 40: 298-305. PMID: 34895785, DOI: 10.1016/j.vaccine.2021.11.065.Peer-Reviewed Original ResearchConceptsLyme disease vaccineDisease vaccineSurvey-weighted descriptive statisticsMultivariable multinomial logistic regression modelsCross-sectional studyLyme disease incidenceHigh incidence areaCross-sectional surveyLogistic regression modelsSafety concernsMultinomial logistic regression modelsVaccine uptakeAdults 45Vaccine parametersVaccine candidatesVaccine attitudesPrevention optionsHealthcare providersWeb-based surveyVaccineSociodemographic characteristicsIncidence areaLyme diseaseDisease incidenceIncidenceHospital-acquired influenza in the United States, FluSurv-NET, 2011–2012 through 2018–2019
Cummings C, O’Halloran A, Azenkot T, Reingold A, Alden N, Meek J, Anderson E, Ryan P, Kim S, McMahon M, McMullen C, Spina N, Bennett N, Billing L, Thomas A, Schaffner W, Talbot H, George A, Reed C, Garg S. Hospital-acquired influenza in the United States, FluSurv-NET, 2011–2012 through 2018–2019. Infection Control And Hospital Epidemiology 2021, 43: 1447-1453. PMID: 34607624, DOI: 10.1017/ice.2021.392.Peer-Reviewed Original ResearchConceptsHospital-acquired influenzaInfluenza-associated hospitalizationsHA influenzaHospital infection control measuresInfluenza Hospitalization Surveillance NetworkFacility-based testingPositive test dateRespiratory symptom onsetAnnual influenza vaccinationHA casesInfection control measuresSymptom onset dateCross-sectional studyYears of agePopulation-based ratesInfluenza vaccinationClinical characteristicsICU careSymptom onsetInfluenza vaccineMechanical ventilationSevere outcomesPatient outcomesInfluenza casesHospitalizationMorbidity and Mortality Among Adults Experiencing Homelessness Hospitalized With COVID-19
Cha S, Henry A, Montgomery M, Laws R, Pham H, Wortham J, Garg S, Kim L, Mosites E, Chai S, Kawasaki B, Meek J, Anderson E, Weigel A, Ryan P, Kim S, Como-Sabetti K, Torres S, Muse A, Bennett N, Billing L, Sutton M, Talbot H, Risk I. Morbidity and Mortality Among Adults Experiencing Homelessness Hospitalized With COVID-19. The Journal Of Infectious Diseases 2021, 224: 425-430. PMID: 33993309, PMCID: PMC8194564, DOI: 10.1093/infdis/jiab261.Peer-Reviewed Original ResearchConceptsMechanical ventilationCOVID-19-associated hospitalizationNon-Hispanic black personsCOVID-19Population-based surveillance dataHealth conditionsChronic health conditionsCoronavirus disease 2019ICU admissionClinical characteristicsRespiratory supportClinical outcomesSevere illnessDisease 2019High riskSurveillance dataAdults Experiencing HomelessnessAnalytic sampleEthnic minority groupsHousing statusBlack personsVentilationDeathOutcomesHospitalization
2020
Human Papillomavirus 16/18–Associated Cervical Lesions: Differences by Area-Based Measures of Race and Poverty
Brackney MM, Gargano JW, Hannagan SE, Meek J, Querec TD, Niccolai LM. Human Papillomavirus 16/18–Associated Cervical Lesions: Differences by Area-Based Measures of Race and Poverty. American Journal Of Preventive Medicine 2020, 58: e149-e157. PMID: 32001053, DOI: 10.1016/j.amepre.2019.12.003.Peer-Reviewed Original ResearchConceptsHuman papillomavirus 16/18Area-based measuresProportion of lesionsCervical lesionsMultivariable logistic regression modelingHuman papillomavirus vaccineLogistic regression modelingPapillomavirus vaccineHuman papillomavirusInsurance statusNew Haven CountyHealth outcomesCensus tract characteristicsSociodemographic characteristicsLesionsIndependent effectsRegression modelingWomenEarly declineSignificant declineEthnicity
2019
Knowledge, attitudes, and behaviors regarding tick-borne disease prevention in endemic areas
Niesobecki S, Hansen A, Rutz H, Mehta S, Feldman K, Meek J, Niccolai L, Hook S, Hinckley A. Knowledge, attitudes, and behaviors regarding tick-borne disease prevention in endemic areas. Ticks And Tick-borne Diseases 2019, 10: 101264. PMID: 31431351, PMCID: PMC10948045, DOI: 10.1016/j.ttbdis.2019.07.008.Peer-Reviewed Original ResearchConceptsEndemic areasPrevalence of LDPrevention behaviorsShowering/bathingTick checksDisease preventionPerceived PrevalenceLyme disease vaccineLD endemic areasInsect repellentSelf-rated knowledgeUnadjusted analysesOdds ratioMultivariable modelFemale genderLD vaccineDisease vaccinePrevention optionsLocal prevalencePreventive behaviorsSociodemographic characteristicsPrevalenceMajority of respondentsOnly factorTick controlMissed Opportunities for HPV Vaccination Among Vaccine-Eligible Women with High Grade Cervical Lesions
Russ SM, Brackney M, Meek J, Niccolai LM. Missed Opportunities for HPV Vaccination Among Vaccine-Eligible Women with High Grade Cervical Lesions. Vaccine 2019, 37: 4262-4267. PMID: 31248688, DOI: 10.1016/j.vaccine.2019.06.061.Peer-Reviewed Original ResearchConceptsHigh-grade cervical lesionsVaccine-eligible womenHPV vaccinationHPV diagnosisProvider recommendationCervical lesionsLog-binomial analysisHuman papillomavirus vaccineCervical intraepithelial neoplasiaStatewide surveillance systemCochran-Armitage trend testSelf-reported barriersArmitage trend testEligible patientsChart reviewHPV vaccinePapillomavirus vaccineVaccination statusCIN 2Intraepithelial neoplasiaVaccine eligibilityPatient interviewsVaccine historyNew Haven CountyVaccination
2017
Risk factors for tick exposure in suburban settings in the Northeastern United States
Mead P, Hook S, Niesobecki S, Ray J, Meek J, Delorey M, Prue C, Hinckley A. Risk factors for tick exposure in suburban settings in the Northeastern United States. Ticks And Tick-borne Diseases 2017, 9: 319-324. PMID: 29174449, DOI: 10.1016/j.ttbdis.2017.11.006.Peer-Reviewed Original ResearchDeclines in Human Papillomavirus (HPV)–Associated High-Grade Cervical Lesions After Introduction of HPV Vaccines in Connecticut, United States, 2008–2015
Niccolai LM, Meek JI, Brackney M, Hadler JL, Sosa LE, Weinberger DM. Declines in Human Papillomavirus (HPV)–Associated High-Grade Cervical Lesions After Introduction of HPV Vaccines in Connecticut, United States, 2008–2015. Clinical Infectious Diseases 2017, 65: 884-889. PMID: 28520854, DOI: 10.1093/cid/cix455.Peer-Reviewed Original ResearchConceptsCervical cancer screeningCervical lesionsRisk behaviorsHPV vaccinationVaccination coverageHuman papillomavirusCancer screeningBirth cohortHigh-grade cervical lesionsHPV vaccination coverageRates of CIN2Cervical intraepithelial neoplasiaHigh-grade lesionsSexual risk behaviorsSignificant declineHPV vaccineVaccine impactIntraepithelial neoplasiaCervical cancerRisk factorsSurveillance periodSimilar epidemiologyChlamydia trachomatisCohort patternsNegative binomial regression
2016
Increased Antiviral Treatment Among Hospitalized Children and Adults With Laboratory-Confirmed Influenza, 2010–2015
Appiah GD, Chaves SS, Kirley PD, Miller L, Meek J, Anderson E, Oni O, Ryan P, Eckel S, Lynfield R, Bargsten M, Zansky SM, Bennett N, Lung K, McDonald-Hamm C, Thomas A, Brady D, Lindegren ML, Schaffner W, Hill M, Garg S, Fry AM, Campbell AP. Increased Antiviral Treatment Among Hospitalized Children and Adults With Laboratory-Confirmed Influenza, 2010–2015. Clinical Infectious Diseases 2016, 64: 364-367. PMID: 28013261, PMCID: PMC5480237, DOI: 10.1093/cid/ciw745.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntiviral AgentsChildChild, PreschoolCohort StudiesFemaleHumansInfantInfant, NewbornInfluenza A Virus, H1N1 SubtypeInfluenza, HumanLength of StayLongitudinal StudiesMaleMiddle AgedOseltamivirPandemicsProspective StudiesRetrospective StudiesSeasonsUnited StatesYoung AdultBenefit of Early Initiation of Influenza Antiviral Treatment to Pregnant Women Hospitalized With Laboratory-Confirmed Influenza
Oboho I, Reed C, Gargiullo P, Leon M, Aragon D, Meek J, Anderson E, Ryan P, Lynfield R, Morin C, Bargsten M, Zansky S, Fowler B, Thomas A, Lindegren M, Schaffner W, Risk I, Finelli L, Chaves S. Benefit of Early Initiation of Influenza Antiviral Treatment to Pregnant Women Hospitalized With Laboratory-Confirmed Influenza. The Journal Of Infectious Diseases 2016, 214: 507-515. PMID: 26908745, DOI: 10.1093/infdis/jiw033.Peer-Reviewed Original ResearchConceptsInfluenza antiviral treatmentSevere influenzaAntiviral treatmentLength of stayPregnant womenEarly initiationInfluenza vaccinationIntensive care unit admissionAnnual influenza vaccinationCare unit admissionLaboratory-confirmed influenzaUnit admissionPregnancy trimesterPreterm deliveryRespiratory failurePulmonary embolismInfluenza seasonMedian ageSeverity strataMechanical ventilationParametric survival analysisIllness onsetInfant morbidityMedian lengthFetal lossEffectiveness of Residential Acaricides to Prevent Lyme and Other Tick-borne Diseases in Humans
Hinckley A, Meek J, Ray J, Niesobecki S, Connally N, Feldman K, Jones E, Backenson P, White J, Lukacik G, Kay A, Miranda W, Mead P. Effectiveness of Residential Acaricides to Prevent Lyme and Other Tick-borne Diseases in Humans. The Journal Of Infectious Diseases 2016, 214: 182-188. PMID: 26740276, PMCID: PMC10874626, DOI: 10.1093/infdis/jiv775.Peer-Reviewed Original ResearchConceptsTick-borne diseasesHuman-tick encountersMajor public health concernPlacebo-controlled trialMedical record reviewHuman tick-borne diseasesReports of illnessPublic health concernPublic health authoritiesTick-borne diseaseRecord reviewTick biteTick exposureTreatment groupsHealth authoritiesDiseaseHealth concernQuesting ticksHuman outcomesTicksUse of acaricidesIllnessIncidenceTrialsWeeks
2015
Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials
Baggs J, Yousey-Hindes K, Ashley ED, Meek J, Dumyati G, Cohen J, Wise ME, McDonald LC, Lessa FC. Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials. Vaccine 2015, 33: 6241-6249. PMID: 26450660, PMCID: PMC4702247, DOI: 10.1016/j.vaccine.2015.09.078.Peer-Reviewed Original ResearchConceptsEmerging Infections ProgramHigh-risk groupRisk groupsRisk scoreIndex hospitalizationHospital dischargeDerivation cohortVaccine trialsValidation cohortDifficile infectionCox proportional hazards modelRisk of CDIAcute care hospitalizationIdentification of patientsClostridium difficile infectionHospital discharge dataNumber of hospitalizationsLow-risk groupProportional hazards modelLarge academic centerAdmission diagnosisPrimary outcomeInpatient stayPatient populationPharmacy dataMonitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008–2012 - Volume 21, Number 9—September 2015 - Emerging Infectious Diseases journal - CDC
Hariri S, Markowitz LE, Bennett NM, Niccolai LM, Schafer S, Bloch K, Park IU, Scahill MW, Julian P, Abdullah N, Levine D, Whitney E, Unger ER, Steinau M, Bauer HM, Meek J, Hadler J, Sosa L, Powell SE, Johnson ML, Group H. Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008–2012 - Volume 21, Number 9—September 2015 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2015, 21: 1557-1561. PMID: 26291379, PMCID: PMC4550135, DOI: 10.3201/eid2109.141841.Peer-Reviewed Original ResearchConceptsHuman papillomavirus vaccineYears of agePapillomavirus vaccineEmerging Infections Program sitesPopulation-based surveillance systemActive population-based surveillanceInfectious Diseases journal - CDCPre-invasive cervical lesionsHPV vaccination historyHPV type distributionPopulation-based surveillanceCervical intraepithelial neoplasiaAcute infectious diseasesRelevant clinical informationCatchment area populationHPV vaccinationHPV typesVaccination historyIntraepithelial neoplasiaCervical cancerCervical lesionsVaccine introductionWomen 18Clinical informationUS populationPneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection—United States, 2005–2008
Garg S, Jain S, Dawood FS, Jhung M, Pérez A, D’Mello T, Reingold A, Gershman K, Meek J, Arnold KE, Farley MM, Ryan P, Lynfield R, Morin C, Baumbach J, Hancock EB, Zansky S, Bennett N, Thomas A, Schaffner W, Finelli L. Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection—United States, 2005–2008. BMC Infectious Diseases 2015, 15: 369. PMID: 26307108, PMCID: PMC4550040, DOI: 10.1186/s12879-015-1004-y.Peer-Reviewed Original ResearchConceptsIntensive care unit admissionSeasonal influenza virus infectionICD-9-CM codesCertain underlying conditionsEmerging Infections ProgramCare unit admissionLaboratory-confirmed influenzaInfluenza virus infectionCause of deathCXR infiltrateUnit admissionICU admissionOlder patientsMechanical ventilationMultivariable analysisUnderlying conditionInfections ProgramChest radiographsVirus infectionPneumoniaSummary diagnosisInfectious diseasesInfluenzaPatientsAdultsObesity not associated with severity among hospitalized adults with seasonal influenza virus infection
Braun ES, Crawford FW, Desai MM, Meek J, Kirley PD, Miller L, Anderson EJ, Oni O, Ryan P, Lynfield R, Bargsten M, Bennett NM, Lung KL, Thomas A, Mermel E, Lindegren ML, Schaffner W, Price A, Chaves SS. Obesity not associated with severity among hospitalized adults with seasonal influenza virus infection. Infection 2015, 43: 569-575. PMID: 26148927, DOI: 10.1007/s15010-015-0802-x.Peer-Reviewed Original ResearchConceptsSeasonal influenza virus infectionMultivariate logistic regression modelSeasonal influenza severityLaboratory-confirmed influenzaRisk of pneumoniaInfluenza virus infectionLogistic regression modelsHospitalized adultsICU admissionObese patientsSevere obesityInfluenza severityArtificial ventilationVirus infectionWeight categoriesObesityPneumoniaSeverityRegression modelsAdultsUnderweightPatientsAdmissionInfectionInfluenzaBurden of Clostridium difficile Infection in the United States
Lessa F, Mu Y, Bamberg W, Beldavs Z, Dumyati G, Dunn J, Farley M, Holzbauer S, Meek J, Phipps E, Wilson L, Winston L, Cohen J, Limbago B, Fridkin S, Gerding D, McDonald L. Burden of Clostridium difficile Infection in the United States. New England Journal Of Medicine 2015, 372: 825-834. PMID: 25714160, PMCID: PMC10966662, DOI: 10.1056/nejmoa1408913.Peer-Reviewed Original ResearchConceptsClostridium difficile infectionDifficile infectionFirst recurrenceHealth care-associated infectionsCommunity-associated infectionsC. difficile infectionCare-associated infectionsPersons 65 yearsLaboratory-based surveillanceType 1 strainsNumber of deathsNational incidenceMolecular typingC. difficileInfectionIncidenceDeathUnited StatesRecurrenceGeographic areasSample of casesEstimated numberRegression modelsActive populationHealth
2014
Child, Household, and Caregiver Characteristics Associated with Hospitalization for Influenza Among Children 6–59 Months of Age
Dharan N, Sokolow L, Cheng P, Gargiullo P, Gershman K, Lynfield R, Morin C, Thomas A, Meek J, Farley M, Arnold K, Reingold A, Craig A, Schaffner W, Bennett N, Zansky S, Baumbach J, Lathrop S, Kamimoto L, Shay D. Child, Household, and Caregiver Characteristics Associated with Hospitalization for Influenza Among Children 6–59 Months of Age. The Pediatric Infectious Disease Journal 2014, 33: e141-e150. PMID: 24642518, PMCID: PMC4025593, DOI: 10.1097/inf.0000000000000283.Peer-Reviewed Original ResearchConceptsMonths of ageChildren 6Influenza hospitalizationsInfluenza illnessInfluenza vaccinationMaternal ageRisk factorsSevere outcomesChronic illnessEmerging Infections Program sitesLaboratory-confirmed influenza infectionIndependent risk factorInfluenza-associated hospitalizationsYoung maternal ageCase-control studyConditional logistic regressionYoung childrenHematologic/Influenza immunizationHousehold smokingEligible casesInfluenza infectionNeurologic conditionsEligible controlsMedical records